BLUE SAIL MEDICAL issues a profit warning, expecting a net loss of 370 million to 470 million yuan for the fiscal year 2024

According to the Zhitong Finance APP, BLUE SAIL MEDICAL has released its annual performance forecast for 2024, expecting a net loss attributable to the parent company of between 370 million yuan and 470 million yuan for the year. During the reporting period, the sales revenue of the cardiovascular and cerebrovascular division exceeded 1.1 billion yuan, a year-on-year increase of approximately 12%. The gross profit margin further improved, continuing the positive trend of annual revenue growth, decreasing sales expense ratio and management expense ratio, and a significant narrowing of operating losses since the national procurement of coronary stents in 2021